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ABSTRACT
Objectives: To investigate the rate of recording of
premenstrual syndrome diagnoses in UK primary care
and describe pharmacological treatments initiated
following a premenstrual syndrome (PMS) diagnosis.
Design: Retrospective cohort study.
Setting: UK primary care.
Participants: Women registered with a practice
contributing to The Health Improvement Network
primary care database between 1995 and 2013.
Primary and secondary outcome measures:
The primary outcome was the rate of first premenstrual
syndrome records per 1000 person years, stratified by
calendar year and age. The secondary outcome was the
proportions of women with a premenstrual syndrome
record prescribed a selective serotonin reuptake
inhibitor, progestogen, oestrogen, combined oral
contraceptive, progestin only contraceptive,
gonadotrophin-releasing hormone, danazol and
vitamin B6.
Results: The rate of recording of premenstrual
syndrome diagnoses decreased over calendar time
from 8.43 in 1995 to 1.72 in 2013. Of the 38 614
women without treatment in the 6 months prior to
diagnosis, 54% received a potentially premenstrual
syndrome-related prescription on the day of their first
PMS record while 77% received a prescription in the
24 months after. Between 1995 and 1999, the majority
of women were prescribed progestogens (23%) or
vitamin B6 (20%) on the day of their first PMS record;
after 1999, these figures fell to 3% for progestogen
and vitamin B6 with the majority of women instead
being prescribed a selective serotonin reuptake
inhibitor (28%) or combined oral contraceptive (17%).
Conclusions: Recording of premenstrual syndrome
diagnoses in UK primary care has declined
substantially over time and preferred prescription
treatment has changed from progestogen to selective
serotonin reuptake inhibitor and combined oral
contraceptives.
BACKGROUND
Premenstrual syndrome (PMS) comprises a
range of physical, psychological and behav-
ioural symptoms experienced by many pre-
menopausal women during the luteal phase
of their menstrual cycle.1 Common symp-
toms include anxiety, irritability, depression,
mood swings, sleep disorders, fatigue, altered
interest in sex, breast tenderness, weight
gain, headaches, change in appetite, general
aches and pain and feeling bloated.1
Premenstrual dysphoric disorder (PMDD), a
severe subtype of PMS, has been deﬁned in
the Diagnostic and Statistical Manual of
Mental Disorders (DSM) as occurring when
a woman suffers from at least ﬁve distinct psy-
chological premenstrual symptoms.2
Prevalence estimates of PMS vary depend-
ing on the methods used to identify and clas-
sify cases. The proportion of women of
reproductive age reporting at least one PMS
symptom has been reported to range
between 50% and 90%, the proportion
reporting severe PMS symptoms or symptoms
that interfere with daily activities to range
between 10% and 30%, and the proportion
meeting the strict DSM PMDD criteria of
having at least ﬁve psychological symptoms to
range between 1% and 8%.3
While the proportion of women of repro-
ductive age suffering clinically relevant PMS
Strengths and limitations of this study
▪ The UK primary care database used in this study
contains data on the routine clinical management
of a representative sample of the UK general
population.
▪ The longitudinal nature of the database allowed
us to report on changes in the recording and
treatment of premenstrual syndrome over an
18-year period (1995–2013).
▪ Cases were ascertained using diagnostic codes
recorded in general practice rather than through
prospective methods, and case certainty is there-
fore less than 100%.
▪ Since the indication for prescriptions is not
recorded in the data source, prescriptions were
assumed to be for premenstrual syndrome
(PMS) based on their timing with regard to the
first PMS diagnosis record.
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symptoms appears to be high, the proportion of women
who seek medical help has been less well studied. A
survey of 300 women in the UK in 1998 classiﬁed 31%
as having severe PMS symptoms, of whom 53% sought
medical help.4 This compares with 45% and 29% of
women with severe premenstrual symptoms seeking
medical attention in the USA and France in 1998,
respectively, while 41% of women with severe PMS in a
separate study in Switzerland reported consulting a
doctor between 1986 and 1993.5
Evidence-based6–13 guidelines for the management of
PMS have been published by the Royal College of
Obstetricians and Gynaecologists (RCOG)14 and, more
recently, by the International Society for Premenstrual
Disorders (ISPMD).15 The RCOG guidelines suggest the
use of exercise, cognitive-behavioural therapy (CBT),
vitamin B6, new generation combined oral contracep-
tives (cyclically or continuously) and/or low dose select-
ive serotonin reuptake inhibitors (SSRIs) (used
continuously or only during the luteal phase) as ﬁrst-line
treatment and the use of oestradiol patches and/or
higher dose SSRIs (also used continuously or only
during the luteal phase) as second-line treatment.
Gondaotrophin analogues (with add-back hormone
replacement therapy) are recommended as third-line
treatment, and total abdominal hysterectomy and bilat-
eral oophorectomy with hormone replacement therapy
as fourth-line treatment. The ISPMD recommends both
SSRIs and all of the oestrogen suppressing treatments
listed above but does not recommend different treat-
ments and dosing schedules for speciﬁc treatment lines.
A study investigating treatments prescribed in UK
primary care on the day of a PMS record found that
between 1993 and 1998 progestogens were the most
commonly prescribed treatment and that vitamin B6 pre-
scribing decreased over the period while SSRI prescrib-
ing increased.6 However, there is little information on
current prescribing practices.
This study seeks to estimate the rate of recording
of PMS diagnoses in UK primary care over a 19-year
period and establish which pharmacological treatments
were most commonly initiated following a PMS
diagnosis.
METHODS
This study was carried out using The Health
Improvement Network (THIN). THIN is an electronic
healthcare database containing the anonymised primary
care medical records of more than 12 million individuals
in the UK general population. Patient data routinely
available in the database include demographic details,
diagnoses and symptoms (including those leading to
hospital admissions), immunisations, pregnancies,
laboratory tests, referrals to specialists, prescriptions
issued by the general practitioner (GP), hospital dis-
charge and clinic summaries and deaths. Clinical events
in primary care are recorded against clinical codes,
known as a Read codes.16 17 There are currently over
100 000 Read codes, each of which is associated with a
short description of varying speciﬁcity. Recording of
additional, unstructured textual information in associ-
ation with a Read code is possible. This information,
commonly referred to as ‘free text’, generally contains
elaborations on the information in the coded record.
The study population consisted of all women registered
with a GP practice contributing to THIN, aged between
12 and 49 years. The follow-up of each woman began at
the latest of 1 January 1995, 182 days after their registra-
tion date, 12 years of age and the date their practice
recording reached acceptable levels.18 19 The follow-up
of each woman ended at the earliest of 1 January 2014,
50 years of age, the date the woman transferred out of
their practice, the date data were last collected from their
practice and the patient’s date of death.
Code lists deﬁning PMS diagnoses and prescriptions
were developed following the method described by Davé
and Petersen and are provided in online supplementary
tables S1 and S2.16 Prescriptions were categorised in one
of the following categories of interest, based on the
British National Formulary: SSRI, progestogen, oestro-
gen, combined oral contraceptive (COC), progesterone
only contraceptive (POC), danazol, gonadotrophin
releasing hormone (GnRH) analogues and vitamin B6.
All women with PMS diagnostic codes recorded during
follow-up were identiﬁed and the rate of recording was
calculated as the number of ﬁrst PMS diagnosis codes
recorded divided by the total amount of follow-up time at
risk. Among individuals with a PMS event, follow-up was
censored at the date of the ﬁrst PMS record. Recording
rates were calculated per 1000 person years and are pre-
sented stratiﬁed by calendar year and age; 95% CIs were
calculated assuming a Poisson distribution.
Among those women with a ﬁrst PMS record meeting
the inclusion criteria, the proportion with a ﬁrst record
of one of the PMS-related drugs listed above in the
6 months before their PMS record was calculated, and
these women were considered prevalent users. We also
estimated the proportion of women by calendar year with
a ﬁrst PMS record meeting the inclusion criteria with a
prescription for PMS-related drugs on the day of their
PMS record or in the 24 months after the PMS record
(but not in the 6 months before the PMS record was
made in the notes). We use cumulative incidence plots to
describe the proportions of individuals initiating each
treatment at the time of, or in the 24 months after, a PMS
record as a function of time. The proportion of women
receiving prescriptions for different types of SSRI and
COC were calculated stratiﬁed by calendar year, and for
SSRIs the daily dose prescribed was also tabulated.
Stata V.13 was used in the management and analysis of
all data.
RESULTS
There were 2 860 143 eligible women contributing 12.6
million person years (PY) of data. Of these, there were
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42 754 individuals with a ﬁrst PMS event recorded pro-
viding an overall rate of recording of 3.38 PMS records
per 1000 PY (95% CI 3.35 to 3.41).
The rate of PMS recording decreased dramatically
over time from 8.43/1000 PY (95% CI 8.02 to 8.85) in
1995 to 1.72/1000 PY (95% CI 1.63 to 1.81) in 2013
(ﬁgure 1). The decrease was relatively rapid between
1995 and 2000, levelled off between 1999 and 2000 and
then began to decrease again after 2000.
The rate of recording of PMS diagnoses increased by
age from 1.21/1000 PY (95% CI 1.13 to 1.28) in those
aged between 11 and 14 years to 5.61/1000 PY (95% CI
5.50 to 5.71) in those aged 35–40 years at which point
the rate peaked and began to fall again reaching 2.07/
1000 PY (95% CI 2.00 to 2.13) in those aged 45–50 years
(table 1).
Ten per cent of women received a prescription for
one of the drugs of interest in the 6 months before their
ﬁrst PMS record. Prevalent treatment remained relatively
stable across the study period for all drug categories
other than COCs. The proportion of women with a
COC prescription in the 6 months before their PMS
record was 9% (141/1567) in 1995 but decreased to
between 2% and 5% between 1996 and 2011.
Fifty-four per cent of women (20 996/38 614) without
a given prescription in the 6 months before their PMS
record had a prescription of interest on the day of diag-
nosis. While the overall proportion receiving a prescrip-
tion of interest remained stable over time, the
proportions initiating speciﬁc drug types changed
(ﬁgure 2). The proportion of women initiating SSRIs
has increased from 2.3% (35/1522) to 27.6% (381/
1380), POCs from 1.1% (17/1545) to 6.2% (87/1403)
and COCs from 10.6% (151/1425) to 17.2% (239/1390)
over the study period (ﬁgure 2A). In contrast, the pro-
portion initiating progestogen has declined from 22.8%
(350/1535) to 2.9% (41/1414), oestrogen from 2.1%
(32/1524) to 0.6% (8/1333) and vitamin B6 from 20.0%
(310/1550) to 3.7% (52/1405; ﬁgure 2B). Prescribing of
GnRH analogues and danazol on the day of a PMS
record was too low (<1%) to observe trends over time.
Seventy-seven per cent of women (29 891/38 614) had
a prescription of interest on the day of their PMS record
or in the 24 months after; this proportion remained
Figure 1 Calendar year specific rates (per 1000 person
years) of first PMS records in UK general practice. PMS,
premenstrual syndrome.
Table 1 Age-specific rates (per 1000 person years) of
first PMS records in UK general practice
Age (years) N IR 95% CI
12–14 1056 1.21 (1.14 to 1.28)
15–19 1975 1.50 (1.43 to 1.57)
20–24 2475 1.80 (1.73 to 1.87)
25–29 5165 3.28 (3.19 to 3.37)
30–34 8947 5.04 (4.94 to 5.15)
35–39 10 768 5.61 (5.50 to 5.71)
40–44 8540 4.39 (4.30 to 4.49)
45–49 3808 2.07 (2.00 to 2.13)
PMS, premenstrual syndrome.
Figure 2 Calendar year specific proportion of women
without a given prescription in the 6 months before their PMS
record who had (A) an SSRI, COC or POC prescription or (B)
a progestogen, oestrogen or vitamin B6 prescription on the
day of their first PMS record. COC, combined oral
contraceptive; PMS, premenstrual syndrome; POC,
progesterone only contraceptive; SSRIs, selective serotonin
reuptake inhibitors.
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stable over time. Figure 3 shows the cumulative propor-
tion of prescriptions in the 24 months following the ﬁrst
PMS record between 2008 and 2011 for each drug type.
With the exception of vitamin B6, the proportion of
women with a prescription in this time period increased
considerably over the 24 months for all drug types such
that by 24 months 44% (3648/8365) had received an
SSRI prescription, 28% (2363/8434) a COC prescrip-
tion, 12% (1030/8475) a progestogen prescription, 20%
(1727/8463) a POC prescription and 3% (293/8557) an
oestrogen prescription.
The type of SSRI prescribed on the day of the ﬁrst
PMS record is shown in ﬁgure 4 as a proportion of all
SSRI prescriptions. Fluoxetine is the most prescribed
SSRI throughout the study period, making up more
than 50% of SSRI prescriptions. Citalopram and, more
recently, sertraline make up an increasing proportion of
SSRI prescriptions over time, while paroxetine and esci-
talopram make up a decreasing proportion. The dose of
SSRI prescribed per day is shown in table 2 and is pri-
marily 10 or 20 mg for citalopram, 5, 10 or 20 mg for
escitalopram, 10 mg for ﬂuoxetine, 10, 20 or 30 mg for
paroxetine and 50 or 100 mg for sertraline.
DISCUSSION
Summary
Recording of PMS diagnoses in UK primary care
decreased substantially between 1995 and 2013, and
among those women with a PMS record, the preferred
treatment has changed from progestogen to SSRIs and
COCs.
Diagnoses
The main limitation of this study relates to the complete-
ness of recording of PMS diagnoses. GPs may record the
symptoms of a woman presenting with PMS, but not
record a speciﬁc PMS diagnosis code. As a result, rates
reported in this study represent the number of recorded
Figure 3 Cumulative incidence of prescriptions in the 24 months following a PMS diagnosis record for the period 2008–2011.
PMS, premenstrual syndrome.
Figure 4 Type of SSRI prescribed on the day of the first
PMS record over time, as a proportion of all SSRI
prescriptions. PMS, premenstrual syndrome; SSRIs, selective
serotonin reuptake inhibitors.
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diagnoses, and are unlikely to reﬂect the ‘true’ inci-
dence of PMS in the community. Since the prevalence
of ‘true’ diagnoses of PMS reported in prospective
studies has not decreased over time,20 we suspect that
the decrease in recording of PMS in primary care is
likely to result from factors that inﬂuence the rate of
consultations for premenstrual symptoms or recording
practices such as changes in the perception of the syn-
drome by women and/or healthcare professionals.
Wyatt et al21 and Weisz and Knaapen22 investigated
PMS recording in UK primary care from 1993 to 1998
and from 2004 to 2006, respectively. Direct comparison
of our results with these two studies is not possible as
the two previous studies used the total number of
primary care consultations as the denominator for their
recording rates. However, similar to our study, these two
studies found that, relative to the prevalence of premen-
strual symptoms reported in the literature, PMS diagno-
ses did not appear to be commonly recorded in UK
primary care. The studies by Wyatt et al21 and Weisz and
Knaapen22 also reported a decrease in recording rates
over time; our results support these ﬁndings and illus-
trate that rates have continued to decrease to 2013.
Prescribing
Since prescriptions in THIN are not speciﬁcally linked
to an indication, we cannot be certain that prescriptions
issued after, or even on the date of, the PMS record
were issued for the treatment of PMS. However, prescrip-
tions issued on the date of a PMS record and not during
the prior 6 months are likely to be speciﬁc to the treat-
ment of PMS. While prescriptions issued over the
24 months after a PMS record are increasingly likely to
be for indications other than PMS, delays between the
ﬁrst PMS record and initiation of pharmacological
treatment may arise due to the completion of symptom
diaries or initiation of non-pharmacological treatments
as a ﬁrst-line approach. As a result, the total proportion
of women prescribed a pharmacological treatment in
primary care after a PMS diagnosis should lie some-
where between the proportion with a prescription on
the date of their PMS record (54%) and the proportion
with a prescription in the 24 months after their PMS
record (77%). If one assumes that women with a PMS
record in our study are primarily those with moderate to
severe symptoms, the above proportions compare with
40% of women in the UK, 44% of women in the USA
and 25% of women in France with self-reported moder-
ate to severe symptoms on prescription treatment in
1998.4
The changes in prescribing from 1995 to 1998
compare favourably with those reported by Wyatt et al21
for this period. Weisz and Knaapen22 reported stable
proportions of prescriptions for different drug types in
the UK over their 3-year study period (2004–2006);
taken in isolation, our data for the same period also
appear relatively stable. Our study, however, by covering
a longer period allowed better observation of the
changes in the type of PMS treatment prescribed over
time with SSRIs and COCs superseding progestogen and
oestrogen as the preferred treatments for PMS in
primary care after 1999. The increasing use of SSRIs
and decreasing use of progestogen in primary care is
largely in line with the evolving evidence base for PMS
treatments with a number of meta-analyses and guide-
lines supporting the effectiveness of SSRIs6 7 and ques-
tioning the effectiveness of progestogens.6 8 The
increased prescribing of COCs is somewhat surprising
given the limited evidence supporting their efﬁcacy in
the treatment of PMS.9 23 24 The limited evidence
Table 2 Type and daily dose of SSRI prescribed on the day of a PMS record
Citalopram Escitalopram Fluoxetine Paroxetine Sertraline
Daily dose (mg) n Per cent n Per cent n Per cent n Per cent n Per cent
5 0 (0) 27 (15.7) 0 (0) 0 (0) 0 (0)
7.5 1 (0.1) 0 (0) 0 (0) 0 (0) 0 (0)
10 452 (30.4) 80 (46.5) 16 (0.3) 26 (4.9) 0 (0)
15 4 (0.3) 0 (0) 0 (0) 1 (0.2) 0 (0)
20 501 (33.7) 18 (10.5) 3880 (79.5) 356 (67.6) 0 (0)
25 0 (0) 0 (0) 0 (0) 0 (0) 3 (0.6)
30 3 (0.2) 0 (0) 3 (0.1) 47 (8.9) 0 (0)
40 67 (4.5) 0 (0) 81 (1.7) 16 (3) 0 (0)
45 0 (0) 0 (0) 0 (0) 1 (0.2) 0 (0)
50 0 (0) 0 (0) 0 (0) 0 (0) 333 (62.6)
60 1 (0.1) 0 (0) 15 (0.3) 1 (0.2) 0 (0)
75 0 (0) 0 (0) 0 (0) 0 (0) 4 (0.8)
100 0 (0) 0 (0) 0 (0) 0 (0) 40 (7.5)
200 0 (0) 0 (0) 0 (0) 0 (0) 5 (0.9)
Unknown 458 (30.8) 47 (27.3) 883 (18.1) 79 (15) 147 (27.6)
Total 1487 (100) 172 (100) 4878 (100) 527 (100) 532 (100)
Fluvoxamine prescriptions (n=4) not shown.
PMS, premenstrual syndrome; SSRI, selective serotonin reuptake inhibitors.
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supporting the efﬁcacy of oestrogen treatment for
PMS25 26 and concerns surrounding its safety may
explain the considerable decline in its use in the treat-
ment of PMS. Notably, while concomitant progestogen
treatment can mitigate some of the risk associated with
oestrogen-based therapy, PMS symptoms produced by
the progestogens limit the efﬁcacy of combined
oestrogen-progestogen therapy as a treatment for PMS.
The preference for COCs over oestrogen therapy may
reﬂect GPs’ greater familiarity with COCs relative to
transdermal oestrogen therapy. Notably, since our data
do not include gynaecologist and psychiatrist prescrib-
ing, the results cannot be generalised to changes in pre-
scribing practices within such specialties.
As pointed out by Wyatt et al,21 the decrease in
vitamin B6 use in 1998 and 1999 is likely to have resulted
from the discovery that high doses might result in per-
ipheral neuropathy and subsequent proposals to restrict
access to the drug. Our data conﬁrm that vitamin B6
prescribing has continued to decrease slightly since
1998. However, since vitamin B6 is also sold over the
counter (OTC), this decrease in use may result from an
increase in the consumption of OTC vitamin B6. Since
Danazol and GnRH analogues are not typically used as
ﬁrst-line or second-line treatment, it is unsurprising that
few women are prescribed these drugs in the 24 months
after their ﬁrst PMS record.
The increasing proportion of SSRI prescriptions for
citalopram and sertraline, decreasing proportion for par-
oxetine and escitalopram and stable proportion for ﬂu-
oxetine are in line with trends in the use of SSRIs in
general in the UK (R McCrea, C Sammon, I Nazareth,
et al. Initiation and duration of selective serotonin
reuptake inhibitor prescribing over time: a UK cohort
study. Br J Psychiatry (manuscript in preparation) 2015).
However, in the general population, the rate of initiation
of citalopram is now greater than that of ﬂuoxetine,
whereas in our study ﬂuoxetine remains the treatment
most commonly initiated on the day of a PMS record (R
McCrea, et al. (Under review) 2015). This difference may
reﬂect the larger evidence base for the use of ﬂuoxetine
for the treatment of premenstrual syndrome, with a
recent meta-analysis7 and systematic review6 including 6–
10 studies on ﬂuoxetine but only one on citalopram. The
doses of each SSRI prescribed were largely in line with
the recommended dose for the treatment of depression
in the UK.27 Unfortunately, no information was available
on the dosing schedule for SSRIs (continuous vs luteal
phase only) or COCs (cyclical vs continuous).
We were unable to investigate the prevalence of use of
non-prescription medications, dietary supplements, com-
plementary and alternative therapies and lifestyle/behav-
iour changes in the treatment of PMS in this study.
While few data on trends in the use of these therapies
for PMS have been published, increases in the use of
these treatment options may have contributed to the
reduction in the use of some of the prescription medica-
tions observed in this study. Additionally, the increased
use of such therapies may lead women not to consult
GPs, thereby contributing to the decreased rate of PMS
diagnoses recorded in primary care.
Conclusions
The recording of PMS diagnoses in UK primary care has
declined between 1995 and 2013. Further work is needed
to establish whether this is due to the decreased record-
ing of PMS diagnoses in the records of women with pre-
menstrual symptoms or whether it is due to a decrease in
the number of women presenting in primary care with
premenstrual symptoms. If the former is true, future
research might investigate how the perception of PMS
among GPs has changed, while if the latter is true future
research might focus on how the perception of PMS
among women has changed and whether the use and/or
efﬁcacy of non-prescription therapies for PMS has inﬂu-
enced women’s healthcare-seeking behaviour. Changes
in the preferred prescription treatment for PMS in
primary care, from progestogens to SSRIs and COCs, are
largely in line with current evidence and guidelines.
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